Search results
Results From The WOW.Com Content Network
The Stanford HIV RT and Protease Sequence Database (also called the “HIV Drug Resistance Database”) was formed in 1998 with HIV reverse transcriptase and protease sequences from persons with well-characterized antiretroviral treatment histories, and is publicly available to query resistance mutations and genotype-treatment, genotype ...
Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden . Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
25 antiretroviral drugs were available in 2009 for the treatment of HIV infection. The drugs belong to six different classes that act at different targets. The most popular target in the field of antiretroviral drug development is the HIV-1 reverse transcriptase (RT) enzyme. [1]
It starts: "In the late 1970s while the epidemic known as 'disco fever' swept through the U.S., an epidemic known as 'junkie pneumonia' raged among injection drug users in New York City." It continues: "Few people were aware that large numbers of [intravenous] drug users were inexplicably dying of pneumonia.
Currently, appearance of drug resistant viruses is an inevitable consequence of prolonged exposure of HIV-1 to antiretroviral therapy. Drug resistance is a serious clinical concern in treatment of viral infection, and it is a particularly difficult problem in treatment of HIV. [25] Resistance mutations are known for all approved NRTIs. [26]
This is a timeline of HIV/AIDS, including but not limited to cases before 1980. Pre-1980s See also: Timeline of early HIV/AIDS cases Researchers estimate that some time in the early 20th century, a form of Simian immunodeficiency virus found in chimpanzees (SIVcpz) first entered humans in Central Africa and began circulating in Léopoldville (modern-day Kinshasa) by the 1920s. This gave rise ...
Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.
This page was last edited on 29 November 2020, at 08:51 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.